3 Mid-Cap Stocks That Will Help You Build Long-Term Wealth
Written by
Yaël Bizouati-Kennedy
Edited by
Daria Uhlig
Commitment to Our Readers
GOBankingRates' editorial team is committed to bringing you unbiased reviews and information. We use data-driven methodologies to evaluate financial products and services - our reviews and ratings are not influenced by advertisers. You can read more about our editorial guidelines and our products and services review methodology.
20 Years
Helping You Live Richer
Reviewed
by Experts
Trusted by
Millions of Readers
Mid-cap stocks, from companies with a market capitalization between $2 billion and $10 billion, according to FINRA, are easy to overlook. Yet, many experts say they’re worth considering because they have room for growth, especially compared to large-cap stocks (market cap between $10 billion and $200 billion) and small-cap stocks (market cap between $250 million and $2 billion).
These stocks are also worth investing in for diversification, as they have the advantages of both small- and large-cap stocks, according to Zacks. The highest-ranked have the potential to enhance their profitability, and they may become large caps over time, Zacks added.
Here are some worth considering:
Crescent Point Energy
Crescent Point Energy is an oil and gas exploration, development and production company operating in the U.S. and Canada.
- Market cap as of May 3: $5.25 billion
- Stock price: $8.50
- Year-to-date: 22.83%
- Past year: 23.9%
- Past month: 0.12%
TipRanks noted that the stock has an average price target of $10.76, which implies a 24.39% upside potential.
Smartsheet
Smartsheet is a software-as-service company whose platform helps distributed teams plan, manage, automate and report on projects.
- Market cap as of May 3: $5.30 billion
- Stock price: $38.58
- Year-to-date: -17.23%
- Past year: -1.58%
- Past month: 1.13%
As TipRanks noted, the stock’s price forecast stood at $47.93, which implies a 24.24% upside.
Exelixis
Exelixis is a biotech company involved in the discovery, development and commercialization of cancer treatments.
- Market cap as of May 3: $6.38 billion
- Stock price: $21.90
- Year-to-date: -8.48%
- Past year: 14%
- Past month: -7.56%
TipRanks reported that the stock has a 21.14% upside.
More From GOBankingRates
Stock data was collected from Google Finance and Yahoo Finance on May 3, 2024.
